ArticleInternational journal of radiation oncology, biology, physics2020
Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments.
Article in International journal of radiation oncology, biology, physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 70 citations in OpenAlex.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Clinical-radiomic model development for local recurrence prediction in stereotactic body radiation therapy-treated lung cancer: comparative analysis with radiobiological models.Scientific reports · 2026Article
- Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.Journal of radiation research · 2026Article
- Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.European journal of medical research · 2026Article
- Dosimetric Challenges of Small Lung Lesions in Low-Density Tissue Treated with Stereotactic Body Radiation Therapy.Journal of clinical medicine · 2026Article
- Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription.Frontiers in medicine · 2026Article
- Feasibility of Very High Cumulative Equivalent Dose in 2 Gy Fraction in Locally Advanced Central/Ultracentral Nonsmall Cell Lung Cancer Treated With Conventional Chemoradiation Therapy and a Stereotactic Boost.Advances in radiation oncology · 2026Article
- In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma.International journal of particle therapy · 2025Article
- A monocentric retrospective analysis of 10-year overall survival after stereotactic body radiotherapy for medically inoperable non-small cell lung cancer.Oncology letters · 2025Article
- Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters.BMC pulmonary medicine · 2025Article
- Effects of target coverage on local recurrence in stereotactic body radiotherapy for early-stage lung squamous cell carcinoma.Japanese journal of radiology · 2025Article
- A Statistical Approach to Assess Biological Equivalent Mean Organ Dose (MOD) for Different Fractionations in Thoracic Radiotherapy.Biomedicines · 2025Article
- Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.PloS one · 2025Article
- Effect of gamma knife stereotactic radiotherapy on the hematological system in patients with advanced lung cancer and its therapeutic effect.American journal of cancer research · 2025Article
- Feasibility and potential clinical benefit of dose de-escalation in stereotactic ablative radiotherapy for lung cancer lesions with ground glass opacities.Physics and imaging in radiation oncology · 2024Article
- Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Multicentric development and evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Dosimetric Analysis of Proximal Bronchial Tree Subsegments to Assess The Risk of Severe Toxicity After Stereotactic Body Radiation Therapy of Ultra-central Lung Tumors.Clinical and translational radiation oncology · 2024Article
- Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience.Clinical and translational radiation oncology · 2024Article
- External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.Frontiers in oncology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 19 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge variation regarding prescription and dose inhomogeneity exists in stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer. The aim of this modeling study was to identify which dose metric correlates best with local tumor control probability to make recommendations regarding SBRT prescription. METHODS AND MATERIALS: We combined 2 retrospective databases of patients with non-small cell lung cancer, yielding 1500 SBRT treatments for analysis. Three dose parameters were converted to biologically effective doses (BEDs): (1) the (near-minimum) dose prescribed to the planning target volume (PTV) periphery (yielding BED
resultsThere were 1500 treatments in 1434 patients; 117 tumors recurred locally. Actuarial local control rates at 12 and 36 months were 96.8% (95% confidence interval, 95.8%-97.8%) and 89.0% (87.0%-91.1%), respectively. In univariable Cox regression, BED
conclusionsBED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.